NASDAQ:NVUS - Novus Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.77 -0.29 (-9.48 %)
(As of 12/19/2018 06:14 AM ET)
Previous Close$3.06
Today's Range$2.75 - $3.06
52-Week Range$2.55 - $8.61
Volume26,700 shs
Average Volume33,800 shs
Market Capitalization$28.83 million
P/E RatioN/A
Dividend YieldN/A
Novus Therapeutics, Inc., a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Receive NVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:NVUS
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio10.69
Quick Ratio10.69


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.75 per share
Price / Book1.01


EPS (Most Recent Fiscal Year)($2.30)
Net Income$-13,110,000.00
Net MarginsN/A
Return on Equity-55.53%
Return on Assets-51.74%


Outstanding Shares9,420,000
Market Cap$28.83 million
OptionableNot Optionable

Novus Therapeutics (NASDAQ:NVUS) Frequently Asked Questions

What is Novus Therapeutics' stock symbol?

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics Inc (NASDAQ:NVUS) issued its quarterly earnings results on Tuesday, November, 13th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.01. View Novus Therapeutics' Earnings History.

When is Novus Therapeutics' next earnings date?

Novus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Novus Therapeutics.

What price target have analysts set for NVUS?

2 Wall Street analysts have issued 1 year target prices for Novus Therapeutics' shares. Their forecasts range from $7.00 to $12.00. On average, they expect Novus Therapeutics' stock price to reach $9.50 in the next year. This suggests a possible upside of 243.0% from the stock's current price. View Analyst Price Targets for Novus Therapeutics.

What is the consensus analysts' recommendation for Novus Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novus Therapeutics.

Has Novus Therapeutics been receiving favorable news coverage?

News articles about NVUS stock have been trending somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novus Therapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term.

Who are some of Novus Therapeutics' key competitors?

Who are Novus Therapeutics' key executives?

Novus Therapeutics' management team includes the folowing people:
  • Mr. Gregory J. Flesher, CEO & Director (Age 48)
  • Dr. Catherine C. Turkel, Pres (Age 57)
  • Mr. Jon Kuwahara CPA, Sr. VP of Fin. & Admin. (Age 53)

Who are Novus Therapeutics' major shareholders?

Novus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.67%), Vanguard Group Inc (1.44%), Vanguard Group Inc. (1.44%) and National Asset Management Inc. (0.48%). Company insiders that own Novus Therapeutics stock include Catherine C Turkel and Gregory J Flesher. View Institutional Ownership Trends for Novus Therapeutics.

Which institutional investors are buying Novus Therapeutics stock?

NVUS stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., Renaissance Technologies LLC and National Asset Management Inc.. Company insiders that have bought Novus Therapeutics stock in the last two years include Catherine C Turkel and Gregory J Flesher. View Insider Buying and Selling for Novus Therapeutics.

How do I buy shares of Novus Therapeutics?

Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novus Therapeutics' stock price today?

One share of NVUS stock can currently be purchased for approximately $2.77.

How big of a company is Novus Therapeutics?

Novus Therapeutics has a market capitalization of $28.83 million. The biopharmaceutical company earns $-13,110,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Novus Therapeutics employs 7 workers across the globe.

What is Novus Therapeutics' official website?

The official website for Novus Therapeutics is

How can I contact Novus Therapeutics?

Novus Therapeutics' mailing address is 19900 MACARTHUR BLVD. SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected]

MarketBeat Community Rating for Novus Therapeutics (NASDAQ NVUS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  312
MarketBeat's community ratings are surveys of what our community members think about Novus Therapeutics and other stocks. Vote "Outperform" if you believe NVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel